• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静脉铁剂治疗:既往出现不良反应后的再次给药

Intravenous Iron Therapy: Re-administration after Prior Adverse Reaction.

作者信息

Aung Tim, Thein Hla, Aung Sandy Tin, Soe Benjamin Tin Aung, Ohnmar Ei

机构信息

General Practice, The Royal Australian College of General Practitioners, Melbourne, VIC, Australia.

General Practice, Star Medical Centre, Logan, QLD, Australia.

出版信息

Korean J Fam Med. 2023 Nov;44(6):350-354. doi: 10.4082/kjfm.23.0039. Epub 2023 Aug 18.

DOI:10.4082/kjfm.23.0039
PMID:37599005
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10667078/
Abstract

BACKGROUND

Intravenous (IV) iron therapy is performed in community practices and hospitals with modern formulations when oral administration becomes impractical. Effective replacement of iron is important for the treatment of iron deficiency and anemia. Can IV iron be rechallenged in individuals with a history of adverse reactions? This review is to explore the challenge of this, when clinically indicated.

METHODS

After performing a literature search, five studies (combined total sample number=1,006) for re-exposure of IV iron to individuals with a history of past reactions were identified, observed, and analyzed. Re-exposure included reactions ranging from mild to moderate and few cases of severe type.

RESULTS

The majority (>80%) of IV iron rechallenges were tolerable, safe, and successful without major serious incidents. There were no reports of major reactions (severe hypersensitivity reactions or anaphylaxis) in these re-exposures.

CONCLUSION

Re-administration of IV iron therapy in patients with a previous adverse reaction is plausible, with benefit and risk stratification. A rechallenge would depend on the nature and degree of the adverse reaction and use of alternative formulations. Rechallenge to a previous severe hypersensitivity reaction or anaphylaxis with the same product has not been reported in these studies. Evidence on the benefit of premedication use is conflicting and requires further studies.

摘要

背景

当口服补铁不可行时,社区诊所和医院会采用现代制剂进行静脉补铁治疗。有效补充铁剂对缺铁和贫血的治疗至关重要。有不良反应史的个体能否再次接受静脉补铁治疗?本综述旨在探讨在临床有指征时这一问题面临的挑战。

方法

在进行文献检索后,确定、观察并分析了五项关于曾有过不良反应史的个体再次接受静脉补铁治疗的研究(合并样本总数 = 1006)。再次暴露包括从轻度到中度的反应以及少数严重类型的反应。

结果

大多数(>80%)再次接受静脉补铁治疗的情况是可耐受、安全且成功的,未发生重大严重事件。这些再次暴露中未报告有重大反应(严重过敏反应或过敏症)。

结论

既往有不良反应的患者再次接受静脉补铁治疗是可行的,但需要进行获益和风险分层。再次给药取决于不良反应的性质和程度以及替代制剂的使用情况。这些研究中未报告使用同一产品对既往严重过敏反应或过敏症进行再次激发试验的情况。关于预防性用药获益的证据存在矛盾,需要进一步研究。

相似文献

1
Intravenous Iron Therapy: Re-administration after Prior Adverse Reaction.静脉铁剂治疗:既往出现不良反应后的再次给药
Korean J Fam Med. 2023 Nov;44(6):350-354. doi: 10.4082/kjfm.23.0039. Epub 2023 Aug 18.
2
Safety of Intravenous Iron Following Infusion Reactions.静脉铁输注后不良反应的安全性。
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1660-1666. doi: 10.1016/j.jaip.2020.11.028. Epub 2020 Nov 26.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
[Hypersensitivity reactions to intravenous iron: an allergist' perspective].[静脉注射铁剂的超敏反应:过敏症专科医生的观点]
Rev Med Suisse. 2022 Apr 6;18(776):639-645. doi: 10.53738/REVMED.2022.18.776.639.
5
Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions.成人既往输注反应史与无既往输注反应史患者的不良事件与静脉铁剂制剂分析。
JAMA Netw Open. 2022 Mar 1;5(3):e224488. doi: 10.1001/jamanetworkopen.2022.4488.
6
Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions.静脉注射铁羧麦芽糖与静脉注射多聚麦芽糖铁治疗缺铁性贫血的安全性比较:一项聚焦急性超敏反应的随机双盲研究的原理与研究设计
J Blood Med. 2017 Sep 26;8:155-163. doi: 10.2147/JBM.S142236. eCollection 2017.
7
Reducing unnecessary premedication prior to parenteral iron therapy: A quality improvement project.减少静脉铁治疗前的不必要预用药:一项质量改进项目。
Transfusion. 2023 Sep;63(9):1685-1691. doi: 10.1111/trf.17502. Epub 2023 Aug 16.
8
A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose.一项系统性文献回顾和荟萃分析评估了铁低聚糖或羧基麦芽糖铁给药后严重或重度过敏反应的发生率。
Int J Clin Pharm. 2023 Jun;45(3):604-612. doi: 10.1007/s11096-023-01548-2. Epub 2023 Apr 3.
9
Prevention and management of acute reactions to intravenous iron in surgical patients.手术患者静脉铁剂急性反应的预防和处理。
Blood Transfus. 2019 Mar;17(2):137-145. doi: 10.2450/2018.0156-18. Epub 2018 Oct 16.
10
Utilization trends and safety of intravenous iron replacement in pediatric specialty care: A large retrospective cohort study.静脉铁替代在儿科专科护理中的利用趋势和安全性:一项大型回顾性队列研究。
Pediatr Blood Cancer. 2018 Jun;65(6):e26995. doi: 10.1002/pbc.26995. Epub 2018 Jan 25.

引用本文的文献

1
The experiences of ferric carboxymaltose desensitization and provocation.羧基麦芽糖铁脱敏和激发试验的经验
World Allergy Organ J. 2025 Jan 17;18(2):101025. doi: 10.1016/j.waojou.2024.101025. eCollection 2025 Feb.
2
Intravenous Iron Versus Oral Iron Administration for the Treatment of Iron Deficiency Anemia: A Patient-Preference Study.静脉注射铁剂与口服铁剂治疗缺铁性贫血:一项患者偏好研究。
Cureus. 2024 Jul 27;16(7):e65505. doi: 10.7759/cureus.65505. eCollection 2024 Jul.

本文引用的文献

1
Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions.成人既往输注反应史与无既往输注反应史患者的不良事件与静脉铁剂制剂分析。
JAMA Netw Open. 2022 Mar 1;5(3):e224488. doi: 10.1001/jamanetworkopen.2022.4488.
2
Risks for Anaphylaxis With Intravenous Iron Formulations : A Retrospective Cohort Study.静脉用铁制剂致过敏反应的风险:一项回顾性队列研究。
Ann Intern Med. 2022 May;175(5):656-664. doi: 10.7326/M21-4009. Epub 2022 Mar 29.
3
Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety.新型静脉用铁剂:化学特性和关键安全性方面的综述——过敏反应、低磷血症和心血管安全性。
Expert Opin Drug Saf. 2021 Jul;20(7):757-769. doi: 10.1080/14740338.2021.1912010. Epub 2021 May 15.
4
Intravenous iron infusion and newer non-dextran formulations.静脉铁输注和较新的非葡聚糖制剂。
N Z Med J. 2021 Apr 30;134(1534):118-127.
5
Management of Hypersensitivity Reactions to Nondextran Iron Products: New Insights Into Predisposing Risk Factors.非右旋糖酐铁产品过敏反应的管理:易患风险因素的新见解。
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2406-2414.e2. doi: 10.1016/j.jaip.2021.01.009. Epub 2021 Jan 21.
6
Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice.缺铁治疗选择及静脉铁在常规临床实践中应用的问答
Ann Med. 2021 Dec;53(1):274-285. doi: 10.1080/07853890.2020.1867323.
7
Safety of Intravenous Iron Following Infusion Reactions.静脉铁输注后不良反应的安全性。
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1660-1666. doi: 10.1016/j.jaip.2020.11.028. Epub 2020 Nov 26.
8
World allergy organization anaphylaxis guidance 2020.世界过敏组织2020年过敏反应指南
World Allergy Organ J. 2020 Oct 30;13(10):100472. doi: 10.1016/j.waojou.2020.100472. eCollection 2020 Oct.
9
Safety of intravenous iron isomaltoside for iron deficiency and iron deficiency anemia in pregnancy.异麦芽糖酐铁静脉注射用于孕期缺铁和缺铁性贫血的安全性。
Arch Gynecol Obstet. 2020 May;301(5):1127-1131. doi: 10.1007/s00404-020-05509-2. Epub 2020 Apr 8.
10
Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults.加拿大专家共识:成人静脉注射铁剂过敏反应的管理
Vox Sang. 2019 May;114(4):363-373. doi: 10.1111/vox.12773. Epub 2019 Apr 2.